Journal: Liver International
Article Title: Curcumin Targets Crispld2 to Suppress Hepatic Stellate Cell Activation via PI3K / AKT Pathway Inhibition in Hepatic Fibrosis
doi: 10.1111/liv.70696
Figure Lengend Snippet: Curcumin treatment suppresses HSC activation by modulating the Crispld2 to mediate the PI3K/AKT axis. (A) KEGG enrichment of Crispld2 in the transitional HSC treatment group. Animal groups: Control, CCl 4 , CCl 4 + Cur (25 mg/kg), CCl 4 + Cur (50 mg/kg); n = 5. (B) WB assessing the protein levels of p‐PI3K, PI3K, p‐AKT, and AKT. Groups of LX‐2 cells treated by TGF‐β: Sh‐NC, sh‐Crispld2. (C) QRT‐PCR quantification of Crispld2 mRNA. (D) WB analysis of Crispld2, p‐PI3K, PI3K, p‐AKT, AKT. Experimental groups of LX‐2 cells with Crispld2 overexpression induced by TGF‐β, following curcumin or LY294002 treatment: Control, Cur + oe‐NC, Cur + oe‐Crispld2, Cur + oe‐Crispld2 + LY294002. ( E) Co‐IP assays confirmed the interaction of CRISPLD2 with PI3K and AKT. (F) CCK‐8 assessing cell viability. (G) Flow cytometry assessing apoptosis. (H) WB for p‐PI3K, PI3K, p‐AKT, AKT and fibrotic proteins (α‐SMA, collagen I, fibronectin, TIMP1). (I, J) ELISA detection of inflammatory cytokines IL‐6 (I) and TNF‐α (J). * p < 0.05.
Article Snippet: We cultured human HSC line LX‐2 (RRID: CVCL_5792; BNCC337957, BNCC, China) in RPMI‐1640 complete medium (BNCC, China) containing 10% FBS (Beyotime, China) and human embryonic kidney 293 T cells (RRID: CVCL_0063; BNCC353535, BNCC, China) in DMEM‐H complete medium (BNCC, China) containing 10% FBS and 2 mM L‐glutamine (MCE, USA).
Techniques: Activation Assay, Control, Quantitative RT-PCR, Over Expression, Co-Immunoprecipitation Assay, CCK-8 Assay, Flow Cytometry, Enzyme-linked Immunosorbent Assay